Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase ll study comparing TS-1 + CDDP (SP) therapy and Capecitabine + CDDP (XP) therapy for patients with metastatic lesions after Surgery plus TS-1 therapy (HERBIS-2).

Next Previous
Trial Profile

A randomized phase ll study comparing TS-1 + CDDP (SP) therapy and Capecitabine + CDDP (XP) therapy for patients with metastatic lesions after Surgery plus TS-1 therapy (HERBIS-2).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Adenocarcinoma; Cancer metastases; Gastric cancer
  • Focus Therapeutic Use
  • Acronyms HERBIS-2

Most Recent Events

  • 02 Jul 2022 Results integrated analysis of three phase II randomized trials (HERBIS-2, HERBIS-4A, and XParTS II) with the use of individual participant data (IPD) from each trial, presented at the 24th World Congress on Gastrointestinal Cancer.
  • 04 Mar 2020 Status changed from discontinued to completed.
  • 25 Jan 2020 Results pooled analysis from HERBIS-2 and HERBIS-4A studies presented at the 2020 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top